Top Markets
Coin of the day
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings, Inc.

AMBS
Clasificación en acciones #41182
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm,... Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine. The company's diagnostic pipeline includes the LymPro test, a blood-based diagnostic designed to detect Alzheimer's disease by analyzing lymphocyte proliferation, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying individuals with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug targeting both Levadopa-Induced Dyskinesia in Parkinson's patients and attention deficit hyperactivity disorders (ADHD). Additionally, they are developing a mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating conditions modeled in animals, such as retinitis pigmentosa and retinal artery occlusion. Amarantus also maintains several specialized platforms: NuroPro, a diagnostic platform dedicated to neurodegenerative diseases with an initial application in Parkinson's; BC-SeraPro, an oncology diagnostic platform specifically for breast cancer; and the PhenoGuard platform, designed for discovering new neurotrophic factors. Beyond these, the company is progressing with Engineered Skin Substitute (ESS), a cell therapy-based product for autologous skin replacement, currently in mid-stage clinical development for severe, life-threatening burns. The company has established a collaborative research and development agreement with both the U.S. Army Institute of Surgical Research and Rutgers University. Established in 2008, Amarantus BioScience Holdings, Inc., which previously operated as Amarantus Bioscience, Inc. until its name change in April 2013, is headquartered in New York, New York.
Precio por acción
$0.0001
Última sincronización: 2026-08-11
Capitalización bursátil
$36.84K
Cambio (1 día)
0.00%
Cambio (1 año)
-66.67%
País
US
Comercio Amarantus BioScience Holdings, Inc. (AMBS)

Categoría

Precio AMBS con Capital del mercado a B
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
AMBS
$0.0001
Capitalización de mercado de Amarantus BioScience Holdings, Inc.(AMBS)
Capitalización bursátil: $36.84K
A fecha de August 2026, Amarantus BioScience Holdings, Inc. tiene una capitalización de mercado de $36.84K. Esto convierte a Amarantus BioScience Holdings, Inc. en la 41182nd empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de Amarantus BioScience Holdings, Inc. desde 2010 hasta 2026
AMBS en comparación con los más populares 5 títulos stocks
Precio por AMBS Activo B Capital del mercado en B Resultados
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
$14,612.41 $36.84K
$5.383T +14,612,413,949.56%
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
$12,006.71 $36.84K
$4.423T +12,006,707,654.24%
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
$11,292.77 $36.84K
$4.160T +11,292,769,909.18%
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
$9,943.60 $36.84K
$3.663T +9,943,597,622.65%
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
$7,847.86 $36.84K
$2.891T +7,847,856,351.78%